Further research could focus on targeting genes such as CRY, Per, Rev-Erb, and ROR alpha through loss-and-gain experiments (e.g., using Rev-Erb alpha agonists), which may lead to novel drug targets for treating insulin resistance and hepatic metabolism. Here, CRYL1 is linked to Insulin resistance.